BIOMAT Database Logo BIOMAT Database Logo

Dual recognition of a human cytotoxic T-cell clone for melanoma antigens. 1996

H Kubo, and J Abe, and F Obata, and H Nakajima, and M Tsunoda, and A Ogawa, and S Nakayama, and Y Beck, and T Kohsaka, and T L Darrow, and Z Abdel-Wahab, and T Saida, and M Takiguchi
Department of Tumor Biology, Institute of Medical Science, University of Tokyo, Japan.

It is well known that tumor-specific CTLs have a crucial role in the elimination of tumors and that different CTL populations recognize tumor antigens in MHC-restricted and MHC-unrestricted manners. We have established two alpha beta CTL clones that recognize melanoma antigens in both human lymphocyte antigen (HLA)-A2-restricted and HLA-unrestricted manners. Flow cytometry analysis showed that these CTL clones carry CD3, CD8, and alpha beta T-cell receptor (TCR) and express low levels of CD56. In contrast, these CTL clones do not express CD16, indicating that they do not contain natural killer cells. TCR analysis of these CTL clones using an anchored PCR method revealed that each clone carries a single alpha beta TCR. Both CTL clones contained the same Valpha and Vbeta gene segments although they carried different Jalpha and Jbeta gene segments. Taken together, these results confirm that CTL clones that carry a single alpha beta TCR recognize melanoma antigens in both HLA-A2-restricted and HLA-unrestricted manners. It is strongly suggested that the dual recognition of these CTL clones for the melanoma antigens is mediated by TCRs. The novel mechanism for antitumor immunity by these CTLs may be important in the effective elimination of tumors in vivo.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

H Kubo, and J Abe, and F Obata, and H Nakajima, and M Tsunoda, and A Ogawa, and S Nakayama, and Y Beck, and T Kohsaka, and T L Darrow, and Z Abdel-Wahab, and T Saida, and M Takiguchi
T-cell recognition of human melanoma antigens.
August 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
H Kubo, and J Abe, and F Obata, and H Nakajima, and M Tsunoda, and A Ogawa, and S Nakayama, and Y Beck, and T Kohsaka, and T L Darrow, and Z Abdel-Wahab, and T Saida, and M Takiguchi
T-cell recognition of melanoma-associated antigens.
March 2000, Journal of cellular physiology,
H Kubo, and J Abe, and F Obata, and H Nakajima, and M Tsunoda, and A Ogawa, and S Nakayama, and Y Beck, and T Kohsaka, and T L Darrow, and Z Abdel-Wahab, and T Saida, and M Takiguchi
[Cytotoxic T-cell immune response against melanoma antigens].
November 1998, Annales de dermatologie et de venereologie,
H Kubo, and J Abe, and F Obata, and H Nakajima, and M Tsunoda, and A Ogawa, and S Nakayama, and Y Beck, and T Kohsaka, and T L Darrow, and Z Abdel-Wahab, and T Saida, and M Takiguchi
An intrathyroidal T-cell clone specifically cytotoxic for human thyroid cells.
May 1987, Immunology,
H Kubo, and J Abe, and F Obata, and H Nakajima, and M Tsunoda, and A Ogawa, and S Nakayama, and Y Beck, and T Kohsaka, and T L Darrow, and Z Abdel-Wahab, and T Saida, and M Takiguchi
Human T cell differentiation antigens characterizing a cytotoxic/suppressor T cell subset.
January 1981, Hybridoma,
H Kubo, and J Abe, and F Obata, and H Nakajima, and M Tsunoda, and A Ogawa, and S Nakayama, and Y Beck, and T Kohsaka, and T L Darrow, and Z Abdel-Wahab, and T Saida, and M Takiguchi
T-cell recognition of melanoma antigens and its therapeutic applications.
January 1997, International journal of clinical & laboratory research,
H Kubo, and J Abe, and F Obata, and H Nakajima, and M Tsunoda, and A Ogawa, and S Nakayama, and Y Beck, and T Kohsaka, and T L Darrow, and Z Abdel-Wahab, and T Saida, and M Takiguchi
Recognition of H-2Kk variant cells by an antiinfluenza cytotoxic T-cell clone.
December 1983, Transplantation proceedings,
H Kubo, and J Abe, and F Obata, and H Nakajima, and M Tsunoda, and A Ogawa, and S Nakayama, and Y Beck, and T Kohsaka, and T L Darrow, and Z Abdel-Wahab, and T Saida, and M Takiguchi
Human papillomavirus antigens and T-cell recognition.
April 2001, Current opinion in infectious diseases,
H Kubo, and J Abe, and F Obata, and H Nakajima, and M Tsunoda, and A Ogawa, and S Nakayama, and Y Beck, and T Kohsaka, and T L Darrow, and Z Abdel-Wahab, and T Saida, and M Takiguchi
Characterization of n-butyl alcohol solubilized, breast tumor specific antigens recognized by a human autologous cytotoxic T-cell clone.
July 1988, Cancer research,
H Kubo, and J Abe, and F Obata, and H Nakajima, and M Tsunoda, and A Ogawa, and S Nakayama, and Y Beck, and T Kohsaka, and T L Darrow, and Z Abdel-Wahab, and T Saida, and M Takiguchi
Specific recognition of influenza virus polymerase protein (PB1) by a murine cytotoxic T-cell clone.
September 1987, Virology,
Copied contents to your clipboard!